CD8A and cancer: Moreover, targeting cathepsin B with cycloastragenol has been shown to enhance CD8+ T cell-mediated antitumor immunity by inhibiting MHC-I degradation [30], further supporting the pivotal role of MHC-I in modulating immune responses to cancer.